Details For Selected Brain Tumor Treatment

Sponsored By

Cleveland Clinic Brain Tumor and Neuro-Oncology Center

Please Click On The Above Banner For More Details

Back to New Treatments List


		Treatment Name:		Phase 1 Study of Azixa (MPC-6827) and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme

		Phase:		Phase 1

		Treatment ID#:		1925

		Age Group:		Adults Only

		Min Karnofsky Score:		60: Requires occasional assistance but is able to care for most of own needs

		Conditions:		Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed

		Last Updated:		08/11/2009

		Tumor Types:		Glioblastoma Multiforme


		Comments:		Azixa (MPC-6827) is a novel small molecule inhibitor of microtubule formation [1] that has demonstrated the ability to inhibit tumor growth in nonclinical testing, with activity in animal models of human melanoma and cancers of the ovary, breast, prostate, colon and pancreas [4]. In nonclinical testing, Azixa has been equally active against multiple drug resistant cancers as with susceptible tumors [2], unlike many of the current options in cancer chemotherapy, a limitation that represents a significant unmet medical need. In mice, the pharmacokinetics of Azixa indicated that the drug distributed rapidly into the brain. The concentration of Azixa in brain tissue was approximately 14 times higher than the plasma concentration and, and at that level, it easily exceeds the concentration required to activate caspase and induce the cancer cell killing apoptosis process in cancer cells [1,3]. Importantly, Azixa was cleared from the brain at a rate similar to that observed from blood [3]. This suggests a special opportunity to study anti-tumor activity in patients with primary brain tumors and brain metastases that currently cannot be treated effectively with chemotherapy due to ineffective drug penetration into the brain.

		Treatment Type:		Chemotherapy

		Contact:		Clinical Trials Office - Huntsman Cancer Institute Huntsman Cancer Institute University of Utah Salt Lake City, UT 84112 USA Phone: 801-581-4477 Fax: E-mail: clinical.trials@hci.utah.edu Website:

Last updated refers to the date when our listing for each treatment was last updated.
ID is a combination of our internal ID and the official ID for the trial, if any.
Min Karnofsky is a general guide to how well you have to function to use this treatment

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2009 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By